Response to intensive induction chemotherapy after failure of frontline azacitidine and venetoclax in acute myeloid leukemia

作者：Kellen Gil, Diana Abbott, Maria L. Amaya, Marc Schwartz, Jonathan A. Gutman, Andrew Kent, Grace Bosma, Daniel A. Pollyea, Christine M. McMahon · 发表于：Leukemia & lymphoma/Leukemia and lymphoma · 年份：2024 · DOI：10.1080/10428194.2024.2397570 · 被引用次数：4 · 研究领域：Acute Myeloid Leukemia Research、Hematopoietic Stem Cell Transplantation、Sarcoma Diagnosis and Treatment

Dear Editor,Venetoclax (Ven) in combination with a hypomethylating agent (HMA) or low dose cytarabine is approved for patients with newly diagnosed acute myeloid leukemia (AML) who are 75 years or ...